Author:
Shimabuco Andrea Y.,Gonçalves Celio R.,Moraes Julio C. B.,Waisberg Mariana G.,Ribeiro Ana Cristina de M.,Sampaio-Barros Percival D.,Goldenstein-Schainberg Claudia,Bonfa Eloisa,Saad Carla G. S.
Funder
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Frederico Foundation
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379–90.
2. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991.
3. Sampaio-Barros PD, van der Horst-Bruinsma IE. Adverse effects of TNF inhibitors in SpA: are they different from RA? Best Pract Res Clin Rheumatol. 2014;28:747–63.
4. Arends S, Brouwer E, Efde M, van der Veer E, Bootsma H, Wink F, et al. Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clin Exp Rheumatol. 2017;35(1):61–8 Epub 2016 Oct 7.
5. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009;36:801–8.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献